Culture System for Isolating Circulating Tumor Cells

Early Detection of Cancer Clinical Trial

Official title:

Culture System for Isolating Circulating Tumor Cells

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03843450
• Other study ID #: 201811053RINA
• Status: Recruiting
• Start date: January 29, 2019
• Est. completion date: September 26, 2022

Study information

• Verified date: September 2020
• Source: National Taiwan University Hospital
• Contact: Tai-Horng Young
• Phone: 23123456
• Email: thyoung[@]ntu.edu.tw
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This culture system utilizes the special affinity difference of biomedical material coating for different cells to achieve the effect of isolating cancer cells from the blood sample. The coating of the system has the characteristic that to make the WBCs adhesion, but the cancer cells in the blood sample suspend in the culture medium, which achieves the effect of separating cancer cells from the blood. The supernatant with the cancer cells can further be isolated from the cultural system for related analysis and detection to achieve early diagnosis and screening.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: September 26, 2022
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Polycythemia patients are between the ages of 20 and 70.

2. Willing to sign the consent form under the informed consent.

Inclusion Criteria:

Exclusion Criteria:

1. Vulnerable Subjects included minors, prisoners, aborigines, pregnant women, people with mental disorders, students, and subordinates, etc.

Related Conditions & MeSH terms

• Early Detection of Cancer
• Neoplastic Cells, Circulating

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cancer Cell Isolation Efficiency of The Isolation System	The percentage isolation of fluorescently-labeled A549 cell lines will be spiked into the whole blood, and the put into the system. The supernatant of the system will be collected to re-culture on the culture dishes and analyzed by fluorescence microscope.	1 day
Primary	WBCs adhesion ratio	The whole blood will be diluted and put into the system. And the supernatant will be collected to count the number of blood cell number by the automatic blood cell count.	1 hour